Healthcare / BiotechnologyTaipei Exchange
$9.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $65000.00 · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.4B
P/E
151.0x
↑EV/EBITDA
83.0x
↑ROE
4.2%
↑Gross Margin
93.0%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+92.8%
FCF CAGR
—
FCF margin
6.3%
FCF / Net income
0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $259.5M · net income $45.2M · FCF $16.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $259.5M | $259.5M | $150.7M | $123.1M | $36.2M |
| Net Income | $45.2M | $45.2M | $-38.6M | $136.7M | $-237.2M |
| EBITDA | $76.6M | $76.6M | $-6.6M | $172.2M | $-200.4M |
| EPS | — | — | -0.05 | 0.19 | -0.33 |
| Gross Margin | 93.0% | 93.0% | 89.3% | 90.7% | 89.7% |
| Operating Margin | 26.7% | 26.7% | -81.0% | -141.9% | -766.4% |
| Net Margin | 17.4% | 17.4% | -25.6% | 111.0% | -654.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.07 | 0.04 |
| Current Ratio | 19.34 | 19.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.4M | $16.4M | $-175.8M | $65000.00 | $-28.7M |
| Returns | |||||
| ROE | 4.2% | 4.2% | -3.6% | 12.2% | -24.4% |
| Valuation | |||||
| P/E | 151.00 | 151.00 | — | 79.47 | — |
| EV/EBITDA | 82.97 | 82.97 | — | 61.14 | — |
| P/B | 6.00 | 6.00 | 7.49 | 9.68 | 11.27 |
| Growth & Yield | |||||
| Revenue Growth | 72.2% | 72.2% | 22.3% | 239.9% | — |
| EPS Growth | — | — | -126.3% | 157.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → n/d
Residual
-10.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.